Kumar Sachin, Sarin Shiv Kumar
Institute of Liver and Biliary Sciences, New Delhi, India.
Hepatol Int. 2013 Mar;7(1):80-7. doi: 10.1007/s12072-012-9398-8. Epub 2012 Sep 25.
Hepatic hydrothorax (HH) is an infrequent but a well-known complication of portal hypertension in patients with end-stage liver disease. The estimated prevalence of HH is around 4-6 % in cirrhotics. Thoracentesis and pleural fluid analysis is a must for establishing the diagnosis of this transudative effusion in the absence of primary cardiopulmonary disease. Management strategies include sodium restriction, diuretics, thoracentesis, transjugular intrahepatic portosystemic shunt, pleurodesis, and video assisted thoracic surgery in selected patients. Liver transplantation remains the ultimate definitive management paradigm. Refractory HH thus warrants prompt consideration of liver transplantation.
肝性胸水(HH)是终末期肝病患者门静脉高压症中一种不常见但广为人知的并发症。肝硬化患者中HH的估计患病率约为4%-6%。在没有原发性心肺疾病的情况下,胸腔穿刺术和胸水分析是确诊这种漏出液的必要手段。治疗策略包括限钠、使用利尿剂、胸腔穿刺术、经颈静脉肝内门体分流术、胸膜固定术,以及对选定患者进行电视辅助胸腔手术。肝移植仍然是最终的确定性治疗模式。因此,难治性HH需要及时考虑肝移植。